MJHS

---

Moldovan Journal of Health Sciences

This article provides an overview of current knowledge and global experience regarding the use of emicizumab, with a focus on its specific considerations in pediatric practice. Emicizumab, a monoclonal antibody, operates uniquely compared to other therapies. It has been approved in Moldova since 2019 for preventing bleeding in hemophilia patients. Significant data from clinical studies and accumulated clinical practice provide answers to most questions physicians have when prescribing emicizumab. The article presents recommendations based on current information and global experience to aid decision-making in emicizumab usage. The purpose of this article is to provide information on management tactics for pediatric patients with hemophilia A receiving emicizumab.

The article discusses oral lichen planus (OLP), a chronic inflammatory disease of unknown etiology characterized by recurrent lesions on the oral mucosa. Despite its prevalence, the exact causes and pathogenesis of OLP are not well understood, and current treatments often yield unsatisfactory results with potential adverse effects.

The article discusses pituitary neuroendocrine tumors, which represent a significant portion of central nervous system tumors, particularly in older adults. It highlights the lack of universal surgical approaches for these tumors, necessitating experienced surgeons for accurate management.